Edition:
United Kingdom

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

92.10USD
7:48pm GMT
Change (% chg)

$-0.56 (-0.60%)
Prev Close
$92.66
Open
$94.40
Day's High
$95.82
Day's Low
$91.89
Volume
44,334
Avg. Vol
59,831
52-wk High
$103.00
52-wk Low
$22.21

Select another date:

Wed, Aug 22 2018

Photo

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

Select another date: